Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
- Author
- R Maréchal, JR Mackey, R Lai, P Demetter, Marc Peeters (UGent) , M Polus, CE Cass, J Young, I Salmon, J Devière and JL Van Laethem
- Organization
- Abstract
- Purpose: Gemcitabine is a promising adjuvant treatment for patients with resected pancreatic adenocarcinoma and its use in combination with radiotherapy is under exploration. Human equilibrative nucleoside transporter 1 (hENT1) and human concentrative nucleoside transporter (hCNT) 1 and 3 are the major transporters responsible for 2',2'-difluoro-2-deoxycytidine (gemcitabine) uptake into cells. The aim of this study was to determine patients' outcome according to the expression of hENT1 and hCNT3 in tumoral cells after postoperative gemcitabine-based chemoradiation regimen. Experimental Design: We studied tumor blocks from 45 pancreatic adenocarcinoma patients treated with gemcitabine-based chemoradiation after curative resection and assessed hENT1 and hCNT3 expression using immunohistochemistry. Results: When adjusted for the effects of lymph node ratio and tumor diameter, patients with high hENT1 expression had significantly longer disease-free survival and overall survival (OS) than patients with low expression, whereas high hCNT3 expression was only associated with longer OS. In a combined analysis, patients with two favorable prognostic factors (hENT1(high)/hCNT3(high) expression) had a longer survival (median OS, 94.8 months) than those having one (median OS, 18.7 months) or no (median OS, 12.2 months) favorable prognostic factor. Conclusions: Pancreatic adenocarcinoma patients with a high expression of hENT1 and hCNT3 immunostaining have a significantly longer survival after adjuvant gemcitabine-based chemoradiation. These biomarkers deserve prospective evaluation in patients receiving gemcitabine-based adjuvant therapy.
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-687135
- MLA
- Maréchal, R., et al. “Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma.” Clinical Cancer Research, vol. 15, no. 8, 2009, pp. 2913–19, doi:10.1158/1078-0432.CCR-08-2080.
- APA
- Maréchal, R., Mackey, J., Lai, R., Demetter, P., Peeters, M., Polus, M., … Van Laethem, J. (2009). Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma. Clinical Cancer Research, 15(8), 2913–2919. https://doi.org/10.1158/1078-0432.CCR-08-2080
- Chicago author-date
- Maréchal, R, JR Mackey, R Lai, P Demetter, Marc Peeters, M Polus, CE Cass, et al. 2009. “Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma.” Clinical Cancer Research 15 (8): 2913–19. https://doi.org/10.1158/1078-0432.CCR-08-2080.
- Chicago author-date (all authors)
- Maréchal, R, JR Mackey, R Lai, P Demetter, Marc Peeters, M Polus, CE Cass, J Young, I Salmon, J Devière, and JL Van Laethem. 2009. “Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma.” Clinical Cancer Research 15 (8): 2913–2919. doi:10.1158/1078-0432.CCR-08-2080.
- Vancouver
- 1.Maréchal R, Mackey J, Lai R, Demetter P, Peeters M, Polus M, et al. Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma. Clinical Cancer Research. 2009;15(8):2913–9.
- IEEE
- [1]R. Maréchal et al., “Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma,” Clinical Cancer Research, vol. 15, no. 8, pp. 2913–2919, 2009.
@article{687135, abstract = {{Purpose: Gemcitabine is a promising adjuvant treatment for patients with resected pancreatic adenocarcinoma and its use in combination with radiotherapy is under exploration. Human equilibrative nucleoside transporter 1 (hENT1) and human concentrative nucleoside transporter (hCNT) 1 and 3 are the major transporters responsible for 2',2'-difluoro-2-deoxycytidine (gemcitabine) uptake into cells. The aim of this study was to determine patients' outcome according to the expression of hENT1 and hCNT3 in tumoral cells after postoperative gemcitabine-based chemoradiation regimen. Experimental Design: We studied tumor blocks from 45 pancreatic adenocarcinoma patients treated with gemcitabine-based chemoradiation after curative resection and assessed hENT1 and hCNT3 expression using immunohistochemistry. Results: When adjusted for the effects of lymph node ratio and tumor diameter, patients with high hENT1 expression had significantly longer disease-free survival and overall survival (OS) than patients with low expression, whereas high hCNT3 expression was only associated with longer OS. In a combined analysis, patients with two favorable prognostic factors (hENT1(high)/hCNT3(high) expression) had a longer survival (median OS, 94.8 months) than those having one (median OS, 18.7 months) or no (median OS, 12.2 months) favorable prognostic factor. Conclusions: Pancreatic adenocarcinoma patients with a high expression of hENT1 and hCNT3 immunostaining have a significantly longer survival after adjuvant gemcitabine-based chemoradiation. These biomarkers deserve prospective evaluation in patients receiving gemcitabine-based adjuvant therapy.}}, author = {{Maréchal, R and Mackey, JR and Lai, R and Demetter, P and Peeters, Marc and Polus, M and Cass, CE and Young, J and Salmon, I and Devière, J and Van Laethem, JL}}, issn = {{1078-0432}}, journal = {{Clinical Cancer Research}}, language = {{eng}}, number = {{8}}, pages = {{2913--2919}}, title = {{Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma}}, url = {{http://doi.org/10.1158/1078-0432.CCR-08-2080}}, volume = {{15}}, year = {{2009}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: